Advertisement

 

 

Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.

Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.
Author Information (click to view)

Wu H, Du Q, Dai Q, Ge J, Cheng X,


Wu H, Du Q, Dai Q, Ge J, Cheng X, (click to view)

Wu H, Du Q, Dai Q, Ge J, Cheng X,

Advertisement

Journal of atherosclerosis and thrombosis 2017 10 05() doi 10.5551/jat.RV17016
Abstract

Atherosclerotic cardiovascular disease (ASCVD) is an inflammatory disease characterized by extensive arterial wall matrix protein degradation. Cysteine protease cathepsins play a pivotal role in extracellular matrix (ECM) remodeling and have been implicated in the development and progression of atherosclerosis-based cardiovascular diseases. An imbalance in expression between cathepsins (such as cathepsins S, K, L, C) and their inhibitor cystatin C may favor proteolysis of ECM in the pathogenesis of cardiovascular disease such as atherosclerosis, aneurysm formation, restenosis, and neovascularization. New insights into cathepsin functions have been made possible by the generation of knockout mice and by the application of specific inhibitors. Inflammatory cytokines regulate the expression and activities of cathepsins in cultured vascular cells and macrophages. In addition, evaluations of the possibility of cathepsins as a diagnostic tool revealed that the circulating levels of cathepsin S, K, and L, and their endogenous inhibitor cystatin C could be promising biomarkers in the diagnosis of coronary artery disease, aneurysm, adiposity, peripheral arterial disease, and coronary artery calcification. In this review, we summarize the available information regarding the mechanistic contributions of cathepsins to ASCVD.

Submit a Comment

Your email address will not be published. Required fields are marked *

fifteen − seven =

[ HIDE/SHOW ]